Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Reata reinforces management team

This article was originally published in Scrip

Executive Summary

Reata Pharmaceuticals has expanded its management team with the appointment of four executives: Dr Paul Audhya, who has previously led drug development at Johnson & Johnson, Bristol-Myers Squibb and Abbott Laboratories, joins as vice-president of development and chief medical officer; Dr Hilary Malone joins as vice-president and chief regulatory and compliance officer from Pfizer, where she was senior vice-president and head of worldwide regulatory strategy; Sean Nolan, who joins Reata as vice-president and chief commercial officer, was previously president of the US entity that emerged following Lundbeck's acquisition of Ovation Pharmaceuticals; and Jim Rouse, most recently executive director of information technology at PharmaNet Development Group, joins as chief information officer. In addition, the company has elected Nancy Wysenski, executive vice-president and chief commercial officer of Vertex Pharmaceuticals, to its board of directors.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts